Abstract

pLG72 is a small, primate-specific protein of 153 amino acids. It is the product of the G72 gene, expressed in testis, spinal cord, and brain. The presence of G72 transcript and pLG72 has recurrently been called into question, however G72 mRNA and pLG72 protein levels were higher in blood and brain of patients with schizophrenia than in healthy controls. On the one hand, the SNP rs2391191 corresponding to the R30K substitution in pLG72 was genetically linked to schizophrenia, reduced thickness of the brain cortex in schizophrenia-affected individuals, and altered memory function. Various lines of evidence indicated that pLG72 is a mitochondrial protein, specifically an extrinsic protein bound on the outer membrane. Over the years, pLG72 was proposed to be involved in different functions: (a) overexpression induces mitochondria fragmentation, increasing the numbers of shorter and more mobile ones which could be delivered faster to regions of intense growth and facilitating the dendritic complexity; (b) it might induce oxidative stress by interacting with methionine-R-sulfoxide reductase B2; and (c) it binds and modulates the activity of FMN-containing oxidoreductase of the respiratory complex I. The main role of this protein, however, is related to its binding to the human flavoenzyme D-amino acid oxidase (hDAAO), i.e., the main catabolic enzyme for D-enantiomer of serine. This D-amino acid is a main endogenous coagonist of the N-methyl-D-aspartate type glutamate receptor (NMDAR) involved in main functions such as synaptic plasticity, learning, memory, and excitotoxicity. For this work, we reviewed the recent literature concerning the hDAAO-pLG72 interaction, focusing on the molecular details of the interaction, the effect of hDAAO function and stability, and the cellular effects, especially on D-serine concentration. The main effects related to the pathological R30K substitution are also reported. We have highlighted the gaps in our knowledge of this human protein as well as the relevance of clarifying the molecular details of hDAAO-pLG72 interaction in order to design molecules to modulate hDAAO activity/stability and thus NMDAR function acting at the D-serine cellular level.

Highlights

  • The G72 and G30 genes were first identified in 2002 on the long arm of chromosome 13 in a linkage study between schizophrenia and single nucleotide polymorphisms (SNPs) (Chumakov et al, 2002; Sacchi et al, 2016)

  • We demonstrated that following a 30-min pre-incubation, pLG72 binding decreases the amount of the flavoenzyme form that is catalytically competent, i.e., the amount of human flavoenzyme D-amino acid oxidase (hDAAO)-bound FAD cofactor that is reduced by D-serine under anaerobic conditions

  • Concerning the stronger inhibition of hDAAO observed for the non-conservative K62E substitution, it can be generated by an additional charge-dipole interaction between E62 in the pLG72 variant and T182 in hDAAO, the two interacting residues identified by cross-linking experiments (Birolo et al, 2016)

Read more

Summary

Introduction

The G72 and G30 genes were first identified in 2002 on the long arm of chromosome 13 in a linkage study between schizophrenia and single nucleotide polymorphisms (SNPs) (Chumakov et al, 2002; Sacchi et al, 2016). Surface plasmon resonance (SPR) analyses showed a slightly stronger interaction with hDAAO for the R30K protein (Kd = 2.2 μM) than for the other pLG72 variants (Sacchi et al, 2017).

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call